European and Developing Countries Clinical Trials Partnership
Partnership / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about European and Developing Countries Clinical Trials Partnership?
Summarize this article for a 10 year old
The European and Developing Countries Clinical Trials Partnership (EDCTP) is a partnership between the European Union (EU), Norway, Switzerland and developing countries and other donors, as well as the pharmaceutical industry, to enable clinical trials and the development of new medicines and vaccines against HIV/AIDS, tuberculosis, and malaria. The need for global action against these diseases in order to promote poverty reduction has been recognised by the United Nations, the G8, and the African Union, and the program envisioned the provision of €600 million for the period 2003–2007 in order to translate medical research results into clinical applications relevant to the needs of developing countries.
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
The European Council adopted the Programme for Action: Accelerated action on HIV/AIDS, malaria and tuberculosis in the context of poverty reduction (COM (2001)96, ) on 15 May 2001, following its launch by the European Commission. The Commission proposal was adopted on 16 June 2003 by the Council and the European Parliament.[permanent dead link] The Programme was to be based on three central pillars: "the impact of existing interventions, the affordability of key pharmaceuticals and trade, and the research and development of specific global public goods." These aims relate specifically with the EU stance on access to essential medicines.